Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

ing for 2006.

Total operating expenses increased to $33.8 million for the year ended December 31, 2007, from $16.1 million for the same period in 2006.

Medivation ended 2007 with $43.3 million in cash and equivalents, plus a remaining capacity of $78.8 million under its committed equity line of credit facility. The Company expects total operating expenses in 2008 to increase significantly beyond 2007 levels, due primarily to further expansion of Dimebon and MDV3100 development, including the upcoming confirmatory pivotal Phase 3 trial of Dimebon in AD and the expanded dosing groups in the ongoing Phase 1-2 trial of MDV3100 in HRPC.

2008 Corporate Milestones

"In 2008, we plan to begin multiple AD clinical trials for Dimebon, including our confirmatory pivotal Phase 3 trial. We also look forward to presenting a steady stream of data across all of our programs in 2008 -- including top-line results from our ongoing Phase 2 trials in Huntington's disease and hormone-refractory prostate cancer," continued Dr. Hung.

During 2008 Medivation intends to:

-- Initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in AD

in the second quarter with the goal of completing the trial and

applying for U.S. and European marketing approval in 2010.

-- Conduct multiple clinical trials of Dimebon in AD for marketing and

reimbursement purposes and to provide a safety database of

approximately 1,500 patients as part of its marketing application. In

the second quarter of 2008, the Company plans to begin the first of

these trials -- a 20 patient Phase 1 trial to evaluate the safety and

tolerability of Dimebon when given to AD patients who are also taking

Aricept(R), the leading AD treatment on the market.

-- Complete the ongoing Phase 2 study of Dimebon in Huntington's disease

in the second quarter.

-- Begin global Phase 3 clinical studie
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ultra-low ... USA, won the Outstanding New Product Award presented on ... and Environmental Repositories (ISBER) at their annual meeting in ... recognizes the company’s development and introduction of the world’s ... was presented to Global Cooling’s CEO Neill Lane by ...
(Date:5/16/2013)... May 16, 2013 A new ... models, from Cole-Parmer is designed to meet the ... includes: , The new Cole-Parmer® MS-3400 Centrifuges ... in the lab. They ensure a powerful and ... specimen separation. Their standard four-place swinging buckets hold ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
(Date:5/16/2013)... YORK , May 16, 2013 ... new market research report is available ... Competitor Analysis: Therapeutic ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The new ...
Breaking Biology Technology:Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8
... Ltd. (NYSE Amex:, SVA ), a leading developer and provider of ... and twelve month,periods ended December 31, 2008. , , ... 2008 sales increasing 39% year-over-year to $46.5, ... in 2008, up from 5.12 million in, ...
... Biotech Ltd. (NYSE Amex:, SVA ), a leading developer and provider ... three and twelve month,periods ended December 31, 2008. , , ... year 2008 sales increasing 39% year-over-year to $46.5, ... Healive(R) in 2008, up from 5.12 million in, ...
... CPHD ) today announced that it will report ... 2009, on Thursday, April 23, 2009, after the close of ... p.m. Pacific Time on Thursday, April 23, 2009, to discuss ... Cepheid,s website at www.cepheid.com/investors at least ...
Cached Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 13Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 14Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 15Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 16Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 17Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 18Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 13Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
(Date:5/17/2013)... residents of all ages will celebrate the science ... on our daily lives during the inaugural Atlanta ... and educators from local museums, corporations, K-12 schools ... 40 different events for children and adults at ... http://atlantasciencefestival.org . , The annual Atlanta Science ...
(Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... undergo polar body diagnosis go on to have a child. ... by researchers in reproductive medicine at Lbeck in an article ... in which they present three successful cases and one failure ... are by-products of normal cell division (meiosis) of an oocytea ...
... of the Americasmight be forgiven for thinking that all ... among dense forest understory are butterflies. In fact, many ... as butterflies, converging on the daytime niche typically dominated ... of the taxonomic relationships among one such group of ...
... usefulness in counting copies of duplicated genome sequences and in ... to be published Aug. 30 in Nature Genetics . ... from one person to the next. The researchers named ... Tool. The study is titled, "Personalized Copy Number and Segmental ...
Cached Biology News:New developments in reproductive medicine 2Moths cloaked in color 2Moths cloaked in color 3Moths cloaked in color 4Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3